Business Context and Reporting Period
Company: Rayonier Advanced Materials Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 14, 2016 (Event Date)
Reporting Period: Specific event reporting; not a periodic financial report.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document reports a contractual event rather than financial performance.
Material Changes and Agreements
- Agreement: Entry into Amendment No. 2 to the Daicel - Rayonier Amended Chemical Specialties Agreement.
- Parties: Daicel Corporation and Rayonier A.M. Sales and Technology Inc. (a subsidiary of the Company).
- Effective Date: January 1, 2016.
- Background: Amends the Original Agreement (effective January 1, 2012) and Amendment No. 1 (effective February 15, 2013).
- Confidentiality: The Company has requested confidential treatment for certain portions of Amendment No. 2, which are redacted in the attached exhibit.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on March 17, 2016, announcing the contract extension with Daicel.
Risks and Contingencies: The filing does not disclose specific new risks or contingencies beyond the standard qualification that the description of the agreement is subject to the full text of the redacted exhibit.
Key Facts for Investor Verification
- Verify the specific terms of the contract extension by reviewing the redacted Exhibit 10.1 (Amendment No. 2) and the March 17, 2016 press release (Exhibit 99.1).
- Note that certain material terms of the agreement are omitted from public view due to a Confidential Treatment Request.
- Confirm the impact of this amendment on future revenue streams, as the filing does not quantify financial implications.